CYLD antibody (C-Term) (FITC)

Catalog No. ABIN7174364

Product Details anti-CYLD Antibody (FITC)

Target: CYLD (Cylindromatosis (Turban Tumor Syndrome) (CYLD))

Binding Specificity: AA 269-435, C-Term

Reactivity: Human

Host: Rabbit

Clonality: Polyclonal

Conjugate: This CYLD antibody is conjugated to FITC

Application: Please inquire

Cross-Reactivity: Human

Purification: >95%, Protein G purified

Immunogen: Recombinant Human Ubiquitin carboxyl-terminal hydrolase CYLD protein (269-435AA)

Isotype: IgG

Application Details

Restrictions: For Research Use only

Handling

Format: Liquid

Buffer: Preservative: 0.03 % Proclin 300
Constituents: 50 % Glycerol, 0.01M PBS, pH 7.4

Preservative: ProClin

Precaution of Use: This product contains ProClin: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Storage: -20 °C,-80 °C

Storage Comment: Upon receipt, store at -20°C or -80°C. Avoid repeated freeze.

Target Details for CYLD

Target: CYLD (Cylindromatosis (Turban Tumor Syndrome) (CYLD))

Alternative Name: CYLD (CYLD Products)

Synonyms: BRSS antibody, CDMT antibody, CYLD1 antibody, CYLDI antibody, EAC antibody, MFT antibody, MFT1 antibody, SBS antibody, TEM antibody, USPL2 antibody, 2010013M14Rik antibody, 2900009M21Rik antibody, C130039D01Rik antibody, mKIAA0849 antibody, cyld antibody, LRRGT00003 antibody, Rp1 antibody, Rp1h antibody, CYLD lysine 63 deubiquitinase antibody, cylindromatosis (turban tumor syndrome), a antibody, CYLD antibody, Cyld antibody, cylda antibody

Background:

Background: Deubiquitinase that specifically cleaves \'Lys-63\'-linked polyubiquitin chains. Has endodeubiquitinase activity. Plays an important role in the regulation of pathways leading to NF-kappa-B activation (PubMed:12917689, PubMed:12917691). Contributes to the regulation of cell survival, proliferation and differentiation via its effects on NF-kappa-B activation (PubMed:12917690). Negative regulator of Wnt signaling (PubMed:20227366). Inhibits HDAC6 and thereby promotes acetylation of alpha-tubulin and stabilization of microtubules (PubMed:19893491). Plays a role in the regulation of microtubule dynamics, and thereby contributes to the regulation of cell proliferation, cell polarization, cell migration, and angiogenesis (PubMed:18222923, PubMed:20194890). Required for normal cell cycle progress and normal cytokinesis (PubMed:17495026, PubMed:19893491). Inhibits nuclear translocation of NF-kappa-B. Plays a role in the regulation of inflammation and the innate immune response, via its effects on NF-kappa-B activation (PubMed:18636086). Dispensable for the maturation of intrathymic natural killer cells, but required for the continued survival of immature natural killer cells. Negatively regulates TNFRSF11A signaling and osteoclastogenesis (By similarity). Involved in the regulation of ciliogenesis, allowing ciliary basal bodies to migrate and dock to the plasma membrane, this process does not depend on NF-kappa-B activation (By similarity). Also able to remove linear (\'Met-1\'-linked) polyubiquitin chains to regulate innate immunity: recruited to the LUBAC complex and, together with OTULIN, restricts linear polyubiquitin formation on RIPK2 in response to NOD2 stimulation (PubMed:26670046, PubMed:26997266).

Aliases: BRSS antibody, CDMT antibody, Cyld antibody, CYLD gene antibody, CYLD_HUMAN antibody, CYLD1 antibody, CYLDI antibody, cylindromatosis (turban tumor syndrome) antibody, cylindromatosis 1 antibody, Deubiquitinating enzyme CYLD antibody, EAC antibody, HSPC057 antibody, KIAA0849 antibody, MFT antibody, MFT1 antibody, Probable ubiquitin carboxyl terminal hydrolase CYLD antibody, SBS antibody, TEM antibody, turban tumor syndrome antibody, Ubiquitin carboxyl-terminal hydrolase CYLD antibody, ubiquitin specific peptidase like 2 antibody, ubiquitin thioesterase CYLD antibody, Ubiquitin thiolesterase CYLD antibody, Ubiquitin-specific processing protease CYLD antibody, Ubiquitin-specific-processing protease CYLD antibody, USPL2 antibody

UniProt: Q9NQC7

Pathways: Apoptosis, Activation of Innate immune Response